Advinus Therapeutics Private Limited

Symantec Corporation

Impetis Biosciences Limited

Advinus Therapeutics Pvt. Ltd.

Meena Patel

Sujay Basu

Dinesh Barawkar

Anil Panmand

Vidya Ramdas

Venkata Poornapragnacharyulu Palle

Yogesh Waman

Bheemashankar A Kulkarni

Basant Rajan

Summon Koul

Venkata Raghavendracharyulu Palle

Kasim Mookhtiar

Yogesh Shejul

Rajesh Bonagiri

Goraksha Khose

Sachin Thorat

Minakshi Naykodi

Rajat Goel

The present disclosure relates to a series of tricyclic compounds, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The disclosure also relates to process of preparation of these tricyclic compounds of Formula I. These compounds are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor. The disclosure also relates to the process of preparation of the tricyclic compounds, and to pharmaceutical compositions containing them.D-A-B—Z  (I)Formula I

Tricyclic compounds, compositions and medicinal applications thereof

The present disclosure relates to a series of tricyclic compounds, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The disclosure also relates to process of preparation of these tricyclic compounds of Formula I. These compounds are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor. The disclosure also relates to the process of preparation of the tricyclic compounds, and to pharmaceutical compositions containing them. Formula (I) wherein D represents a tricyclic ring system selected from: Formula (II) or Formula (III). 

The present invention discloses substituted fused pyrimidine compounds of formula (I), their tautomers, polymorphs, stereoisomers, solvates, pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity; the compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor, such as asthma, chronic obstructive pulmonary disorder, angiogenesis, pulmonary fibrosis, emphysema, allergic diseases, inflammation, reperfusion injury, myocardial ischemia, atherosclerosis, hypertension, congestive heart failure, retinopathy, diabetes mellitus, obesity, inflammatory gastrointestinal tract disorders, and/or autoimmune diseases. 

Substituted fused pyrimidine compounds

The present disclosure relates to fused tricyclic compounds of formula (I) or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2A adenosine receptor antagonists. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2A receptor. Such conditions include, but are not limited to, Parkinsons disease, restless leg syndrome, Alzheimers disease, neurodegenerative disorder, inflammation, wound healing, dermal fibrosis, nocturnal myoclonus, cerebral ischaemia, myocardial ischemia, Huntington's disease, multiple system atrophy, corticobasal degeneration, Wilson's disease or other disorders of basal ganglia which results in dyskinesias, post traumatic stress disorder, hepatic cirrhosis, sepsis, spinal cord injury, retinopathy, hypertension, social memory impairment, depression, neuroprotection, narcolepsy or other sleep related disorders, attention deficit hyperactivity disorder, drug addiction, post traumatic stress disorder and vascular injury and the like. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them. 

Fused tricyclic compounds as adenosine receptor antagonist

A method and apparatus for streaming applications to a plurality of clients within a peer-to-peer network is provided. In one embodiment, a method for distributing application blocks to facilitate application streaming within a peer-to-peer network includes processing location information regarding a plurality of data chunks amongst a plurality of clients, wherein the plurality of data chunks form at least a portion of an application block and communicating the location information amongst the plurality of clients, wherein the location information is used to request at least one data chunk of the plurality of data chunks.

Method and apparatus for streaming applications to a plurality of clients within a peer to-peer network

The present disclosure relates to purine compounds of formula (I) or formula (II) or its tautomers, polymorphs, stereoisomers, solvates or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2B adenosine receptor antagonists. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2B receptor. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.

Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications

The present invention discloses substituted fused pyrimidine compounds of formula (I), their tautomers, polymorphs, stereoisomers, solvates, pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor, such as asthma, chronic obstructive pulmonary disorder, angiogenesis, pulmonary fibrosis, emphysema, allergic diseases, inflammation, reperfusion injury, myocardial ischemia, atherosclerosis, hypertension, congestive heart failure, retinopathy, diabetes mellitus, obesity, inflammatory gastrointestinal tract disorders, and/or autoimmune diseases. 

A method and apparatus for securing sensitive data from misappropriation by malicious software is provided. In one embodiment, the method for securing sensitive data from misappropriation by malicious software includes examining a history to identify potentially compromised sensitive data upon an occurrence of the malicious software and notifying a user regarding the potentially compromised sensitive data.

Method and apparatus for securing sensitive data from misappropriation by malicious software

Compounds of the present disclosure are fused pyrimidine compounds of formula (I), its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts thereof, as Adenosine receptor antagonists. Processes of their preparation are also described in the disclosure.

Heterocyclic compounds as adenosine receptor antagonist

A computer-implemented method for monitoring physical paths within a computer network may include: 1) identifying a first logical path within a computer network, 2) identifying a physical path that corresponds to the first logical path, 3) probing the physical path to determine whether the first logical path is active, 4) identifying a second logical path within the computer network, 5) determining that the physical path also corresponds to the second logical path, and then 6) using the results of the probe of the physical path to determine whether the second logical path is active without probing the physical path a second time. Additional computer-implemented methods for monitoring physical paths within multi-host computer networks are also disclosed.

Growing community of inventors

Pune, India

Meena Patel